Drug intelligence / Profile preview

SIF001

Development stage: Phase 1
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SIF001 is a monoclonal antibody under investigation for the treatment of drug-resistant epilepsy. The drug is being studied for its efficacy and safety in patients who have not responded to conventional antiepileptic therapies. As a monoclonal antibody, it likely acts by targeting specific molecular pathways involved in seizure activity, though the precise mechanism of action has not been publicly disclosed. The development and clinical evaluation are taking place in China[2].

Other names: SIF001SIF-001SIF 001

Beyond the preview

Go deeper on SIF001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIF001.

Explore the full profile